Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II allogeneic CARCIK-CD19 trial in relapsed/refractory B-cell NHL and CLL
2023-505511-20-00Phase 2Authorised
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Jan 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CARCIK-CD19 in mature B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Fondazione Matilde Tettamanti. Primary endpoints: Dose-limiting toxicity and Overall response rate. Planned start Jan 2024; status: authorised.
02
Drugs
CARCIK-CD19
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-505511-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505511-20-00.